Literature DB >> 28398508

Examining the validity of the rheumatoid arthritis magnetic resonance imaging score according to the OMERACT filter-a systematic literature review.

Thasia G Woodworth1, Olga Morgacheva1, Olga L Pimienta2, Orrin M Troum2, Veena K Ranganath1, Daniel E Furst1.   

Abstract

Objective: To examine whether the RA MRI score (RAMRIS) for RA of the wrist/hand meets the OMERACT filter criteria-truth (validity), discrimination and feasibility.
Methods: We conducted a systematic literature review in PubMed and Scopus, from 1970 through June 2014, focused on MRI measures of synovitis, osteitis/bone marrow oedema, erosions and/or joint space narrowing in RA randomized controlled trials and observational studies with cohort size ⩾10. Strength of evidence was assessed using the Cochrane Handbook criteria.
Results: Of 634 MRI titles/abstracts, 202 met the review criteria, with 92 providing at least 1 type of validity. Four articles provided criterion validity, and 26 articles utilized RAMRIS to assess 1.5 T MRI images. Histopathology data showed inflammation corresponding to MRI of synovitis and osteitis. MRI erosions corresponded to those identified with CT. Content and construct validity for RAMRIS synovitis, osteitis and erosions were documented by correlations with clinical, laboratory and/or radiographic data. Each measure was sensitive to change and responsive to therapy. RAMRIS synovitis and osteitis were able to discriminate between the efficacy of treatments vs placebo in 12-week studies, whereas RAMRIS erosions required studies of ⩾24 weeks.
Conclusion: RAMRIS synovitis, osteitis and erosions imaged with 1.5 T MRI are valid and useful for evaluating joint inflammation and damage for RA of the wrist/hand, according to the OMERACT filter.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  MRI; OMERACT filter; RAMRIS; clinical trials; magnetic resonance imaging; rheumatoid arthritis; rheumatoid arthritis magnetic resonance imaging score; structural progression

Mesh:

Substances:

Year:  2017        PMID: 28398508      PMCID: PMC5850856          DOI: 10.1093/rheumatology/kew445

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  59 in total

1.  Bilateral MR imaging of the hand and wrist in early and very early inflammatory arthritis: tenosynovitis is associated with progression to rheumatoid arthritis.

Authors:  Márcio Navalho; Catarina Resende; Ana Maria Rodrigues; Filipa Ramos; Augusto Gaspar; J Alberto Pereira da Silva; João Eurico Fonseca; Jorge Campos; Helena Canhão
Journal:  Radiology       Date:  2012-06-21       Impact factor: 11.105

Review 2.  Rheumatoid arthritis.

Authors:  David L Scott; Frederick Wolfe; Tom W J Huizinga
Journal:  Lancet       Date:  2010-09-25       Impact factor: 79.321

3.  2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group.

Authors:  Andrea D Furlan; Victoria Pennick; Claire Bombardier; Maurits van Tulder
Journal:  Spine (Phila Pa 1976)       Date:  2009-08-15       Impact factor: 3.468

4.  Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI.

Authors:  Claudia Schirmer; Alexander K Scheel; Christian E Althoff; Tania Schink; Iris Eshed; Alexander Lembcke; Gerd-Rüdiger Burmester; Marina Backhaus; Bernd Hamm; Kay-Geert A Hermann
Journal:  Ann Rheum Dis       Date:  2006-10-26       Impact factor: 19.103

5.  Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.

Authors:  A K Brown; M A Quinn; Z Karim; P G Conaghan; C G Peterfy; E Hensor; R J Wakefield; P J O'Connor; P Emery
Journal:  Arthritis Rheum       Date:  2006-12

6.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.

Authors:  Mark A Quinn; Philip G Conaghan; Philip J O'Connor; Zunaid Karim; Adam Greenstein; Andrew Brown; Clare Brown; Alexander Fraser; Stephen Jarret; Paul Emery
Journal:  Arthritis Rheum       Date:  2005-01

7.  Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.

Authors:  Maria Pilar Lisbona; Joan Maymo; Javier Perich; Miriam Almirall; Carolina Pérez-García; Jordi Carbonell
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

8.  OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Exercise 3: an international multicenter reliability study using the RA-MRI Score.

Authors:  Marissa Lassere; Fiona McQueen; Mikkel Østergaard; Philip Conaghan; Ron Shnier; Charles Peterfy; Mette Klarlund; Paul Bird; Philip O'Connor; Neal Stewart; Paul Emery; Harry Genant; John Edmonds
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

9.  Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis.

Authors:  Iris Eshed; Eugen Feist; Christian E Althoff; Bernd Hamm; Eli Konen; Gerd-R Burmester; Marina Backhaus; Kay-Geert A Hermann
Journal:  Rheumatology (Oxford)       Date:  2009-05-27       Impact factor: 7.580

10.  High-resolution MRI of the wrist and finger joints in patients with rheumatoid arthritis: comparison of 1.5 Tesla and 3.0 Tesla.

Authors:  Gero Wieners; Jacqueline Detert; Florian Streitparth; Maciej Pech; Frank Fischbach; Gerd Burmester; Jens Ricke; Marina Backhaus; Harald Bruhn
Journal:  Eur Radiol       Date:  2007-01-12       Impact factor: 7.034

View more
  6 in total

Review 1.  MRI of synovitis and joint fluid.

Authors:  Christopher J Burke; Hamza Alizai; Luis S Beltran; Ravinder R Regatte
Journal:  J Magn Reson Imaging       Date:  2019-01-08       Impact factor: 4.813

2.  The value of ultrasound and magnetic resonance imaging scoring systems in explaining handgrip strength and functional impairment in rheumatoid arthritis patients: a pilot study.

Authors:  Fausto Salaffi; Marina Carotti; Marco Di Carlo; Luca Ceccarelli; Sonia Farah; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2022-05-14       Impact factor: 6.313

3.  Reliability of Magnetic Resonance Imaging (MRI) Scoring of the Metatarsophalangeal Joints of the Foot according to the Rheumatoid Arthritis MRI Score.

Authors:  Yousra J Dakkak; Xanthe M E Matthijssen; Désirée van der Heijde; Monique Reijnierse; Annette H M van der Helm-van Mil
Journal:  J Rheumatol       Date:  2019-09-15       Impact factor: 4.666

4.  Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study.

Authors:  Marco A Cimmino; Massimiliano Parodi; Francesca Barbieri; Stefano Bombardieri; Giuseppe Zampogna; Annamaria Iagnocco; Alberto Batticciotto; Luca Maria Sconfienza; Luigi Sinigaglia; Fabrizio De Benedetti; Fabiola Atzeni; Piercarlo Sarzi-Puttini
Journal:  Biologics       Date:  2020-02-11

Review 5.  Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis.

Authors:  Varvara Choida; Margaret Hall-Craggs; Bethany R Jebson; Corinne Fisher; Maria Leandro; Lucy R Wedderburn; Coziana Ciurtin
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

6.  Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).

Authors:  Tomohiro Shimizu; Hyo Jin Choi; Ursula Heilmeier; Matthew Tanaka; Andrew J Burghardt; Jingshan Gong; Nattagan Chanchek; Thomas M Link; Jonathan Graf; John B Imboden; Xiaojuan Li
Journal:  Arthritis Res Ther       Date:  2017-10-04       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.